---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Daratumumab and Hyaluronidase-fihj - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/daratumumabandhyaluronidase-fihj
version: v1
---

# Daratumumab and Hyaluronidase-fihj - NCI

# Daratumumab and Hyaluronidase-fihj

Placeholder slot

(DAYR-uh-TOOM-yoo-mab … HY-al-yoo-RAH-nih-days)

This page contains brief information about daratumumab and hyaluronidase-fihj
and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Darzalex Faspro

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4bb241af-4299-4373-8762-2d6709515db0)

## Use in Cancer

Daratumumab and hyaluronidase-fihj
is approved to be used alone or with other drugs to treat adults with:

- **light-chain [amyloidosis](/Common/PopUps/popDefinition.aspx?id=45507&version=Patient&language=English)** that is newly diagnosed. It is used with [bortezomib](/Common/PopUps/popDefinition.aspx?id=269133&version=Patient&language=English),
[cyclophosphamide](/Common/PopUps/popDefinition.aspx?id=45253&version=Patient&language=English), and [dexamethasone](/Common/PopUps/popDefinition.aspx?id=45262&version=Patient&language=English).¹
- **[multiple myeloma](/Common/PopUps/popDefinition.aspx?id=45793&version=Patient&language=English)**:
- For newly diagnosed cancer, it is used:
- with bortezomib, dexamethasone, and either [thalidomide](/Common/PopUps/popDefinition.aspx?id=45458&version=Patient&language=English) or lenalidomide in patients who can receive an [autologous stem cell transplant](/Common/PopUps/popDefinition.aspx?id=270733&version=Patient&language=English)
- with bortezomib, [melphalan](/Common/PopUps/popDefinition.aspx?id=45957&version=Patient&language=English), and [prednisone](/Common/PopUps/popDefinition.aspx?id=45492&version=Patient&language=English) or with [lenalidomide](/Common/PopUps/popDefinition.aspx?id=393761&version=Patient&language=English) and dexamethasone in patients who cannot receive an autologous stem cell transplant
- For cancer that has come back or did not respond to treatment, it is used:
- with dexamethasone and either lenalidomide or bortezomib in patients who have received at least one therapy
- with [pomalidomide](/Common/PopUps/popDefinition.aspx?id=589401&version=Patient&language=English) and dexamethasone in patients who have received at least one therapy that included lenalidomide and a proteasome inhibitor
- with [carfilzomib](/Common/PopUps/popDefinition.aspx?id=737706&version=Patient&language=English) and dexamethasone in patients who have received one to three types of therapy
- alone in patients who have already received at least three types of therapy that included a [proteasome inhibitor](/Common/PopUps/popDefinition.aspx?id=393541&version=Patient&language=English) and an [immunomodulating agent](/Common/PopUps/popDefinition.aspx?id=739791&version=Patient&language=English) or whose cancer did not respond to a proteasome inhibitor and an immunomodulatory agent

¹This use is approved under FDA’s [Accelerated Approval Program](https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm). As a condition of approval, [confirmatory trial(s)](/Common/PopUps/popDefinition.aspx?id=799146&version=Patient&language=English) must show that daratumumab and hyaluronidase-fihj provides a clinical benefit in these patients.

Daratumumab and hyaluronidase-fihj is a form of [daratumumab](/Common/PopUps/popDefinition.aspx?id=776992&version=Patient&language=English) that is given as a [subcutaneous](/Common/PopUps/popDefinition.aspx?id=45914&version=Patient&language=English) [injection](/Common/PopUps/popDefinition.aspx?id=44678&version=Patient&language=English). This form can be given in less time than daratumumab, which is given as an [infusion](/Common/PopUps/popDefinition.aspx?id=45738&version=Patient&language=English). For more information about daratumumab that may apply to daratumumab and hyaluronidase-fihj, see the Drug Information Summary for [Daratumumab](/about-cancer/treatment/drugs/daratumumab).

Daratumumab and hyaluronidase-fihj
is also being studied in the treatment of other types of
cancer.

## More About Daratumumab and Hyaluronidase-fihj

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/795698) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Daratumumab and Hyaluronidase-fihj](https://medlineplus.gov/druginfo/meds/a620040.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Targeted Therapy to Treat Cancer](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

[Monoclonal Antibodies](https://www.cancer.gov/about-cancer/treatment/types/immunotherapy/monoclonal-antibodies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Daratumumab And Hyaluronidase-fihj](https://www.cancer.gov/research/participate/clinical-trials/intervention/C156401) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
